MicroSigX Advances M3CRC with New Data and China Launch Plans
At DDW 2025, MicroSigX presented updated interim results from its international multicenter study on M3CRC, a novel microbial gene marker test for colorectal cancer screening. The data continues to show high sensitivity and specificity in detecting advanced neoplasia, reinforcing M3CRC’s potential to transform non-invasive screening.
“M3CRC is on track to become a new standard in colorectal cancer screening,” said Rachel Fan, CEO of MicroSigX. “The diversity of our cohort strengthens the findings, and we expect to complete the full nine-center study in near future.”
MicroSigX is also preparing for market entry in China, now in the stage of clinical trial, which is the final stage of the NMPA approval process.
“We’re excited to bring this innovation to millions in China,” Fan added. “Earlier detection means better outcomes and lower healthcare costs.”
Stay tuned as we move closer to broader clinical integration.
#MicroSigX
#M3CRC
#ColorectalCancer
#CancerScreening
#DiagnosticsInnovation
#HealthcareImpact
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
